Ziconotide (Prialt) for Chronic Pain
The FDA has approved ziconotide (Prialt - Elan) intrathecal infusion for management of severe chronic pain in patients who are intolerant of or refractory to other treatments. Ziconotide is a synthetic neuronal N-type calcium channel blocker. It is intended for use with a programmable implanted microinfusion device, but an external microinfusion device can be used temporarily....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Ziconotide (Prialt) for Chronic Pain
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1223
Article Code: 1223d
Date: December 5, 2005
Volume: 47
Pages: 103-104
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1223
Article Code: 1223d
Date: December 5, 2005
Volume: 47
Pages: 103-104
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)